{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Colinz Laboratories Ltd
Are Colinz Laboratories Ltd latest results good or bad?
Colinz Laboratories Ltd's Q3 FY26 results show a slight revenue increase of 2.88% to ₹1.43 crores, but a significant net profit decline of 42.86% to ₹0.08 crores, indicating challenges in profitability and operational efficiency despite a debt-free balance sheet. Overall, the results reflect ongoing struggles in a competitive market, necessitating strategic improvements.
Colinz Laboratories Q3 FY26: Marginal Revenue Growth Masks Deeper Profitability Concerns
Colinz Laboratories Ltd., a micro-cap pharmaceutical formulations manufacturer, reported a modest quarterly performance for Q3 FY26, with net profit declining 42.86% quarter-on-quarter to ₹0.08 crores from ₹0.14 crores in Q2 FY26. On a year-on-year basis, net profit increased 60.00% from ₹0.05 crores in Q3 FY25, though this comparison benefits from an exceptionally weak base quarter. With a market capitalisation of just ₹13.00 crores, the Mumbai-based company continues to struggle with scale and profitability consistency, as reflected in its current stock price of ₹46.20, down 47.91% from its 52-week high of ₹88.70.
Colinz Laboratories Ltd is Rated Strong Sell
Colinz Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 11 June 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 26 December 2025, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Why is Colinz Labs falling/rising?
On 19-Dec, Colinz Laboratories Ltd witnessed a sharp decline in its share price, falling by 7.6% to close at ₹48.05. This drop follows a three-day losing streak, reflecting mounting concerns over the company’s weak financial performance and its inability to keep pace with broader market gains.
Colinz Labs Sees Revision in Market Evaluation Amidst Challenging Financial Trends
Colinz Labs, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting ongoing challenges in its financial and operational metrics. This development highlights shifts in the company’s quality, valuation, financial trends, and technical outlook, providing investors with a clearer understanding of its current standing within a competitive industry.
Why is Colinz Labs falling/rising?
As of 14-Nov, Colinz Laboratories Ltd is currently priced at 42.74, reflecting a recent increase and strong performance with a total return of 7.49% over four days. Despite this, the stock remains down 38.73% year-to-date, indicating long-term struggles compared to the Sensex's gain of 8.22%.
Colinz Laboratories Hits New 52-Week Low at Rs. 36.11
Colinz Laboratories has reached a new 52-week low of Rs. 36.11, reflecting a year-to-date decline of 32.98%. Despite recent gains over three days, the company faces challenges such as weak long-term fundamentals and low return on equity, while the broader market shows mixed performance.
Colinz Laboratories Hits New 52-Week Low at Rs. 37.4
Colinz Laboratories has reached a new 52-week low, reflecting a significant downturn in its stock performance. The company has underperformed its sector and experienced a notable decline over the past year, with weak financial metrics contributing to its challenges in the market.
Why is Colinz Labs falling/rising?
As of 06-Nov, Colinz Laboratories Ltd's stock price is Rs 39.81, down 9.99%, significantly underperforming its sector and the broader market. The stock has seen a notable decline in investor participation and has consistently traded below key moving averages, indicating negative sentiment.
Colinz Laboratories Ltd Faces 9.99% Decline Amid Significant Selling Pressure and Ongoing Losses
Colinz Laboratories Ltd is experiencing substantial selling pressure, with its stock declining significantly over various time frames. The company has faced consecutive losses, underperforming against the Sensex and its sector. Factors contributing to this trend include trading below key moving averages and ongoing challenges in its market position.
Are Colinz Labs latest results good or bad?
Colinz Laboratories' latest Q2 FY26 results are concerning, showing an 11.46% decline in net sales and compressed operating margins, despite a slight sequential improvement in net profit. Overall, the company faces significant challenges with deteriorating revenue trends and questions about earnings quality.
Is Colinz Labs overvalued or undervalued?
As of November 3, 2025, Colinz Labs is overvalued with a PE ratio of 42.76 and a year-to-date decline of 35.64%, indicating a concerning long-term outlook despite a recent short-term gain.
How has been the historical performance of Colinz Labs?
Colinz Labs has experienced a downward trend in net sales, reporting 6.53 Cr in March 2025, down from 7.03 Cr in March 2024. Despite a slight increase in profit after tax to 0.50 Cr, negative cash flow and declining revenues raise concerns about its financial stability.
Colinz Laboratories Q2 FY26: Micro-Cap Pharma's Troubling Revenue Decline Continues
Colinz Laboratories Ltd., a micro-cap pharmaceutical manufacturer with a market capitalisation of ₹20.00 crores, reported its Q2 FY26 results that underscore deepening operational challenges. The company posted a net profit of ₹0.14 crores for the quarter ended September 2025, representing a modest 16.67% sequential increase from Q1 FY26 but a concerning 12.50% decline year-on-year. More troubling is the persistent revenue erosion, with net sales declining 25.27% YoY to ₹1.39 crores, marking the third consecutive quarter of double-digit YoY revenue contraction.
Why is Colinz Labs falling/rising?
As of 03-Nov, Colinz Laboratories Ltd is seeing a price increase to Rs 44.90, up 8.11%, with significant intraday gains and increased investor participation. Despite a year-to-date decline, the stock has outperformed the Sensex recently, indicating positive investor sentiment.
Is Colinz Labs overvalued or undervalued?
As of October 31, 2025, Colinz Labs is fairly valued with a PE ratio of 39.55 and an EV to EBIT of 14.07, but has underperformed significantly with a year-to-date return of -40.47%, contrasting with a 7.42% gain in the Sensex.
Is Colinz Labs overvalued or undervalued?
As of October 31, 2025, Colinz Labs is fairly valued with a PE ratio of 39.55, an EV to EBITDA ratio of 14.07, and a ROE of 5.07%, but has underperformed with a year-to-date return of -40.47% compared to the Sensex's 7.42%.
Is Colinz Labs overvalued or undervalued?
As of October 31, 2025, Colinz Labs is fairly valued with a PE ratio of 39.55, an EV to EBITDA of 14.07, and a ROCE of 10.08%, positioning it in the middle of its industry valuation spectrum despite a year-to-date stock decline of 40.47%.
Colinz Laboratories Ltd Gains 10.69% Over Three Days, Currently Down 6.78% Today
Colinz Laboratories Ltd, a microcap in the Pharmaceuticals & Biotechnology sector, has seen increased buying activity, gaining for three consecutive days. However, its overall performance lags behind the broader market, with declines noted over various time frames, indicating volatility and mixed investor sentiment.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
